Department of Urology, Faculty of Medicine, Universitas Brawijaya, Saiful Anwar General Hospital, Malang, East Java, Indonesia.
Med Arch. 2023 Feb;77(1):13-17. doi: 10.5455/medarh.2023.77.13-17.
Following the c In the management of BPH, Tamsulosin is an example of a-adrenergic receptor blocker drug that is usually used. In addition, dutasteride is also a BPH drug that works as a group of 5 a reductase inhibitor. However, the weakness of long-term administration of a1-adrenergic receptor antagonists can result in upregulation of prostate smooth muscle cell contractility and expression of a-adrenergic mRNA receptors, resulting in hyperactivity and supersensitivity to a-agonists.
Our study aimed to determine the effect of long-term administration of tamsulosin, dutasteride and tamsulosin-dutasteride combination on the contractility of prostate smooth muscle cells in BPH model rats.
This study was designed using an experimental post test only method, control group design. It measured the contractility of prostate smooth muscle cells from samples obtained from the prostatic stroma of experimental animals adult male Rattus norvegicus Wistar strain induced BPH and administered tamsulosin 1 mg/kg/day, dutasteride 0.5 mg/kg/day, and a combination of continuous administration for 1, 6 and 12 consecutive days. Data were analyzed using one way ANOVA if the data distribution was normal or Kruskall Walis if the data distribution was abnormal.
The effect of tamsulosin, dutasteride and the combination of tamsulosin with dutasteride on prostate smooth muscle cell contractility in experimental animals Rattus norvegicus Wistar strain showed that tamsulosin administration for six days, twelve days, and the combination of tamsulosin dutasteride for one day got statistically significant different result (p=0.016; p=0.006; p=0.029) compared to the negative control group. In addition, there was a difference between the tamsulosin and dutasteride combination group for 12 days compared to tamsulosin monotherapy for 6 days and 12 days (p=0.160; p=0.010).
Continuous administration of monotherapy tamsulosin has an upregulation effect on the sixth to twelfth day. Decreased contractility of prostate smooth muscle cells occurs on the first day but will increase on the sixth to twelfth day. On the other hand, the results of our study also showed that the combination of tamsulosin and dutasteride gave the effect of reducing contractility and was most effective on day 12.
在 BPH 的治疗中，坦索罗辛是一种常用的α-肾上腺素能受体阻滞剂药物。此外，度他雄胺也是一种 BPH 药物，作为 5α-还原酶抑制剂。然而，长期使用α1-肾上腺素能受体拮抗剂会导致前列腺平滑肌细胞收缩性上调和α-肾上腺素能 mRNA 受体表达，从而导致对α-激动剂的过度活跃和超敏性。
我们的研究旨在确定长期给予坦索罗辛、度他雄胺和坦索罗辛-度他雄胺联合治疗对 BPH 模型大鼠前列腺平滑肌细胞收缩性的影响。
本研究采用实验后测试仅方法、对照组设计。它测量了从诱导 BPH 的实验动物成年雄性 Wistar 大鼠前列腺基质中获得的前列腺平滑肌细胞的收缩性，并连续给予坦索罗辛 1mg/kg/天、度他雄胺 0.5mg/kg/天和联合治疗 1、6 和 12 天。如果数据分布正常，则使用单因素方差分析进行分析，如果数据分布异常，则使用 Kruskal-Wallis 检验进行分析。
坦索罗辛、度他雄胺和坦索罗辛与度他雄胺联合治疗对实验动物 Wistar 大鼠前列腺平滑肌细胞收缩性的影响表明，坦索罗辛治疗 6 天、12 天和坦索罗辛-度他雄胺联合治疗 1 天与阴性对照组相比具有统计学显著差异（p=0.016;p=0.006;p=0.029）。此外，坦索罗辛和度他雄胺联合治疗组与坦索罗辛单药治疗 6 天和 12 天相比，第 12 天也存在差异（p=0.160;p=0.010）。
连续给予单药坦索罗辛在第六天至第十二天具有上调作用。前列腺平滑肌细胞收缩性在第一天下降，但在第六天至第十二天会增加。另一方面，我们的研究结果还表明，坦索罗辛和度他雄胺联合治疗可降低收缩性，在第 12 天效果最佳。
